Pharmacoeconomic report: Eculizumab (Soliris) Alexion Pharma Canada Corporation : indication : adult patients with generalized myasthenia gravis
Based on CADTH reanalysis, eculizumab plus SOC compared to SOC alone is associated with an ICER of $1,505,712 per quality-adjusted life-year (QALY) gained and has a 0% probability of being cost-effective for patients with refractory AChR-antibody-positive generalized myasthenia gravis (gMG) at a wil...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2020, December 2020
|
| Edition: | Version: Final |
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Table of Contents:
- Includes bibliographical references